By efrat|2023-11-05T06:48:14+00:00November 4th, 2023|All|Comments Off on Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD
By efrat|2023-10-29T10:30:21+00:00October 26th, 2023|All|Comments Off on Oct 30th 2023- Prof. Robert Zeiser- Phase 2 Study of Natalizumab Plus Standard Corticosteroid Treatment for High-Risk Acute GVHD
By efrat|2023-10-22T07:35:02+00:00October 20th, 2023|All|Comments Off on Oct 23rd 2023- Prof. Didier Blaise- Real World Experience of CAR T Cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
By efrat|2023-10-12T06:33:16+00:00October 15th, 2023|All|Comments Off on Oct 16th 2023- Dr. Enrique Ocio- Melflufen Plus Dexamethasone and Daratumumab or Bortezomib in Relapsed/Refractory MM
By efrat|2023-09-21T07:15:03+00:00October 1st, 2023|All|Comments Off on Oct 2nd 2023- Dr. Paul Richardson- Mezigdomide plus Dexamethasone in Relapsed and Refractory Myeloma
By efrat|2023-09-20T11:10:36+00:00September 24th, 2023|All|Comments Off on Sept 25th 2023- Dr. Akshay Sharma- CRISPR- Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
By efrat|2023-09-18T07:55:03+00:00September 12th, 2023|All|Comments Off on Sept 19th 2023- Prof. Ephraim Fuchs- Cytokine Release Syndrome in Haploidentical Stem Cell Transplant May Impact T-cell Recovery and Relapse
By efrat|2023-09-10T05:56:01+00:00September 10th, 2023|All|Comments Off on Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report
By efrat|2023-09-06T07:40:11+00:00September 6th, 2023|All|Comments Off on Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
